Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Antihero
|
| gptkbp:administered_by |
oral medication
|
| gptkbp:approves |
gptkb:1954
gptkb:FDA |
| gptkbp:atccode |
B01 AA03
|
| gptkbp:available_on |
generic medication
|
| gptkbp:brand |
gptkb:Coumadin
gptkb:Jantoven |
| gptkbp:casnumber |
81400-97-5
|
| gptkbp:chemical_formula |
C19 H16 O4
|
| gptkbp:contraindication |
pregnancy
severe liver disease active bleeding |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
gptkb:tablet
injection 2-10 mg daily |
| https://www.w3.org/2000/01/rdf-schema#label |
warfarin sodium
|
| gptkbp:interacts_with |
NSAIDs
antibiotics antidepressants herbal supplements |
| gptkbp:is_monitored_by |
INR (International Normalized Ratio)
|
| gptkbp:mechanism_of_action |
inhibits vitamin K epoxide reductase
|
| gptkbp:patient_education |
report any unusual bleeding
inform healthcare providers about use avoid vitamin K-rich foods regular INR monitoring required |
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver half-life of 20-60 hours |
| gptkbp:related_to |
gptkb:Cardiology
gptkb:deep_vein_thrombosis gptkb:atrial_fibrillation stroke thrombosis pulmonary embolism venous thromboembolism valvular heart disease embolism |
| gptkbp:research_areas |
anticoagulation therapy
pharmacogenomics patient adherence drug interactions dosing strategies |
| gptkbp:side_effect |
nausea
bruising bleeding hair loss |
| gptkbp:used_for |
preventing blood clots
|
| gptkbp:bfsParent |
gptkb:Coumadin
|
| gptkbp:bfsLayer |
5
|